Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Trimmed by Guggenheim Capital LLC

Guggenheim Capital LLC cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 31.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,235 shares of the company's stock after selling 2,414 shares during the period. Guggenheim Capital LLC's holdings in Medpace were worth $1,739,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its holdings in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. boosted its position in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the period. Proficio Capital Partners LLC grew its stake in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. increased its position in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after buying an additional 30 shares during the period. Institutional investors own 77.98% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on MEDP shares. Leerink Partners assumed coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Leerink Partnrs upgraded Medpace to a "hold" rating in a research report on Monday, March 24th. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and lowered their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Robert W. Baird cut their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Medpace has a consensus rating of "Hold" and an average target price of $349.30.

Medpace Trading Up 4.2 %

NASDAQ:MEDP traded up $12.30 during mid-day trading on Thursday, reaching $302.84. 501,885 shares of the stock were exchanged, compared to its average volume of 339,150. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The firm has a market capitalization of $9.15 billion, a PE ratio of 23.98, a PEG ratio of 3.81 and a beta of 1.46. The business has a fifty day moving average price of $315.38 and a 200 day moving average price of $332.24.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the previous year, the firm earned $3.20 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.